# A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer

> **NCT07890597** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Pfizer** · enrollment: 3800 (estimated)

## Conditions studied

- Early Breast Cancer
- Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-)

## Interventions

- **DRUG:** Atirmociclib
- **DRUG:** giredestrant
- **OTHER:** Atirmociclib placebo

## Key facts

- **NCT ID:** NCT07890597
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12-01
- **Primary completion:** 2032-04-13
- **Final completion:** 2042-08-20
- **Target enrollment:** 3800 (ESTIMATED)
- **Last updated:** 2026-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07890597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07890597, "A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer". Retrieved via MORVS 2026-11-22 from https://api.morvs.ai/clinical/NCT07890597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*
